Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 14/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 14/20 | 0.67 |
| ▸ | HTT | P42858 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | POLB | P06746 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | CCR6 | P51684 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 7/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.63 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.63 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213360 | 0.84 | KMT2A (0.68) | KDM4EMEN1KMT2AHTTMAPT | |
| SCHEMBL16863007 | 0.81 | KDM4E (1.00) | KDM4EMEN1KMT2AHTTMAPT | |
| SCHEMBL22668259 | 0.78 | HTT (0.77) | KDM4EHTTMAPTPOLBRAB9A | |
| SCHEMBL8618712 | 0.77 | MEN1 (0.73) | KDM4EMEN1KMT2AHTTMAPT | |
| SCHEMBL19450676 | 0.77 | MEN1 (0.63) | KDM4EMEN1KMT2AHTTMAPT | |
| SCHEMBL16213338 | 0.77 | MEN1 (0.76) | KDM4EMEN1KMT2AHTTMAPT | |
| SCHEMBL5529962 | 0.76 | MAPT (0.68) | KDM4EMEN1KMT2AHTTMAPT | |
| SCHEMBL13401373 | 0.76 | MEN1 (0.62) | KDM4EMEN1KMT2AHTTMAPT | |
| SCHEMBL11200203 | 0.76 | MEN1 (0.62) | KDM4EMEN1KMT2AHTTMAPT | |
| SCHEMBL4235162 | 0.76 | MEN1 (0.70) | KDM4EMEN1KMT2AHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | claimed |
| WO-2007030939-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | KDM4E 4479/4885MEN1 3865/4885KMT2A 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.